BioVie Inc

BioVie, Inc. is a biopharmaceutical company, which engages in discovery, development, and marketing drug therapies for liver disease. The company was founded on April 10, 2013 and is headquartered in Carson City, NV.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q1 2025

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioVie, Inc. is a biopharmaceutical company, which engages in discovery, development, and marketing drug therapies for neurological and neurodegenerative disorders and liver disease. The company was founded on April 10, 2013 and is headquartered in Carson City, NV.

BioVie Inc (NASDAQ:BIVI) has announced positive results from two Phase 2 trials assessing NE3107's potential in Parkinson's Disease (PD) and Alzheimer's Disease (AD). The NM201 study (NCT05083260) is a double-blind, placebo-controlled, safety, tolerability, and pharmacokinetics study in Parkinson's disease (PD) participants treated with carbidopa/levodopa and NE3107.

BioVie announces positive results from two Phase 2 trials assessing NE3107's potential in Parkinson's Disease and Alzheimer's Disease

Initial Data shows NE3107 may Reduce Horvath DNA Methylation SkinBlood Clock by 3.3 years after 3 months of treatment Initial Data shows NE3107 may Reduce Horvath DNA Methylation SkinBlood Clock by 3.3 years after 3 months of treatment

BioVie Announces Additional Findings from Phase 2 Alzheimer's Disease Trial: NE3107 Appears to Impact Biomarkers of Aging-Related Disease States in Addition to Observed Reversal of Cognitive Decline in Dementia

NE3107-treated patients experienced greater motor control in Parkinson's trial

BioVie Announces Positive Results for NE3107 in Parkinson's and Alzheimer's Phase 2 Trials

Company is Opting to Increase Study Size to 400 due to Fast Enrollment Pace Company is Opting to Increase Study Size to 400 due to Fast Enrollment Pace

BioVie's Phase 3 Trial Assessing NE3107 in Alzheimer's Disease Has Fully Enrolled the Targeted 316 Patients

Here is how BioVie Inc. (BIVI) and Immunovant, Inc. (IMVT) have performed compared to their sector so far this year.

Are Medical Stocks Lagging BioVie (BIVI) This Year?

CARSON CITY, Nev., Nov. 15, 2022 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that three abstracts highlighting results of its Phase 2, open-label study of NE3107 in patients with Alzheimer's Disease (AD) were accepted for presentation at the 2022 Clinical Trials on Alzheimer's Disease (CTAD) Annual Meeting, to be held November 29-December 2, 2022 in San Francisco, CA.

BioVie to Present Data from Investigator-Sponsored Exploratory Biomarker and Imaging Trial of NE3107 for the Treatment of Alzheimer's Disease at CTAD Annual Meeting

The mean of analysts' price targets for BioVie Inc. (BIVI) points to an 84% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Think BioVie Inc. (BIVI) Could Surge 84%: Read This Before Placing a Bet

Is BioVie (BIVI) Stock Outpacing Its Medical Peers This Year?

Acumen Pharmaceuticals

Athira Pharma

Anavex Life Sciences

Biogen

Eli Lilly

Prothena

Roche Holding AG

Cassava Sciences Inc

The Clinical Trials on Alzheimer's Conference will take place from November 29, 2022 to December 2, 2022. Representatives of several listed companies will present data, including Eisai, Anavex, BioVie, Athira Pharma, Cassava Sciences and NervGen.

Trading Ideas On The Upcoming CTAD 2022 Conference

CARSON CITY, Nev., Oct. 24, 2022 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that an abstract characterizing the hospitalization burden of patients with cirrhosis and ascites and receiving treatment via paracentesis has been selected for presentation at The Liver Meeting 2022, the annual meeting of the American Association for the Study of Liver Diseases (AASLD). The Liver Meeting 2022 will be held Washington, DC, from November 4-6, 2022.

BioVie to Present Data on Characterizing Hospitalization Burden of Ascites at AASLD Liver Meeting 2022

Topline Data Expected December 2022 Topline Data Expected December 2022

BioVie's Phase 2 Trial Assessing NE3107's Pro-motoric Activity in Parkinson's Disease is Fully Enrolled

BioVie recently presented one of the best cognition improvements ever reported in an open label study in Alzheimer's disease. Further reporting and biomarkers confirmed those improvements, making BioVie a serious contender in the Alzheimer's space.

BioVie: Recent Data In Alzheimer's Suggests +100% Upside Potential Within A Year

RENO, Nev., Sept. 29, 2022 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and neurological and neurodegenerative disorders, today announced the participation of its management team in a panel discussion and one-on-one investor meetings at Cantor Fitzgerald's Neurology & Psychiatry Conference, to be held October 6-7, 2022, in San Francisco, CA.

BioVie to Participate in Cantor Fitzgerald's Neurology & Psychiatry Conference

In a fresh press release from this morning, BioVie (NASDAQ: BIVI ) disclosed top-line results from a Phase 2 clinical trial for its Alzheimer's disease treatment, NE3107. The results were largely positive, and today's traders are pushing BIVI stock higher as a result.

BioVie (BIVI) Stock Pops on Positive Alzheimer's Trial Results

BioVie Inc. shares BIVI, +22.42% rose 19% in premarket trade Wednesday, after the biotech announced positive results from a Phase 2 trial of its Alzheimer's Disease treatment NE3107. Moving away from the past focus in Alzheimer's drug development on Amyloid Beta and phospho-tau, the lesions found in the brains of patients, the treatment targets neuroinflammation and insulin resistance, the company said in a statement.

BioVie shares soar 19% premarket after company announces positive results from Phase 2 trial of Alzheimer's treatment

BioVie Provides Updates on Other Clinical Programs BioVie Provides Updates on Other Clinical Programs

BioVie and Dr. Sheldon Jordan Jointly Announce Topline Results from an Investigator-Sponsored Exploratory Biomarker and Imaging Trial of NE3107 for the Treatment of Alzheimer's Disease

Earlier June coverage of BioVie showed the company's potential in Alzheimer's and Parkinson's. Since that coverage, the company seems to have been set up for success.

BioVie: Possibly Setting Up For Success With Alzheimer's And Parkinson's Results Imminent

CARSON CITY, Nev., June 23, 2022 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) ("BioVie" or "Company"), a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and neurological and neurodegenerative disorders, today announced that a patent covering the use of terlipressin monotherapy to treat ascites patients who have not progressed to hepatorenal syndrome (“HRS”) has been issued by the U.S. Patent & Trademark Office. This action restores U.S. patent protection for BIV201 (continuous infusion terlipressin), which had previously been lost due to an Inter Partes Review (“IPR”) challenge to a related patent by another company.

BioVie Announces Patent Issuance Covering Ascites Treatment with BIV201

CARSON CITY, Nev., April 25, 2022 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and neurological and neurodegenerative disorders, today announced the participation of its management team in a fireside chat and one-on-one meetings at the B. Riley Securities' Neuro & Ophthalmology Conference, to be held virtually April 27-28, 2022.

BioVie to Participate at the B. Riley Securities' Neuro & Ophthalmology Conference

CARSON CITY, Nev., March 10, 2022 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI), a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and neurological and neurodegenerative disorders, today announced that an interview with President and CEO Cuong Do will air on The RedChip Money Report® on Bloomberg TV, March 12, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the United States.

BioVie Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report®

RENO, Nev., March 09, 2022 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and neurological and neurodegenerative disorders, today announced the participation of its management team in a presentation and one-on-one investor meetings at the Oppenheimer Virtual Annual Healthcare Conference, to be held March 15-17, 2022.

BioVie to Participate at the Oppenheimer Virtual Annual Healthcare Conference

RENO, Nev., Jan. 20, 2022 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and neurological and neurodegenerative disorders today announced the treatment of the first patient in the Company's Phase 2 clinical trial assessing the potential pro-motoric impact of its NE3107 asset in Parkinson's disease patients.

BioVie Announces Treatment of First Patient in Phase 2 Clinical Trial of NE3107 for the Treatment of Parkinson's Disease

RENO, Nev., Dec. 28, 2021 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and neurological and neurodegenerative disorders, today announced the participation of its management team in a panel and in one-on-one investor meetings at the LifeSci Partners 11th Annual Corporate Access Event, to be held virtually January 5-7, 2022.

BioVie to Participate at the LifeSci Partners 11th Annual Corporate Access Event

Campaign to Improve Education on Ascites Due to Liver Cirrhosis and Raise Awareness of BioVie's Phase 2b Study of BIV201 for Refractory Ascites Campaign to Improve Education on Ascites Due to Liver Cirrhosis and Raise Awareness of BioVie's Phase 2b Study of BIV201 for Refractory Ascites

BioVie Announces Partnership with the American Liver Foundation

RENO, Nev., Dec. 01, 2021 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, entered into a debt facility with Avenue Venture Opportunities Fund, L.P. and Avenue Venture Opportunities Fund II, L.P. (Collectively “the Avenue Venture Funds”) providing up to $25 million with the initial $15 million funded at the close on November 30, 2021.

News for BioVie Inc Stock (BIVI)